AI finds a common target for liver cancer and ageing
Live Forever Club - 28-Dec-2025Two genes cut liver cancer growth and harmful senescent cells in lab studies
Join the club for FREE to access the whole archive and other member benefits.
Two genes cut liver cancer growth and harmful senescent cells in lab studies
A hybrid quantum–AI system designed and validated new KRAS inhibitors in early lab tests
OpenAI-backed Chai raises $130M to accelerate drug and antibody design with AI
Personalized coaching boosts healthy habits and self-care for multimorbidity patients
ISM3830 boosts immune attack and delivers strong preclinical tumour control
Lila Sciences aims to speed up breakthroughs by pairing powerful AI with massive robotic labs
VCPI will generate massive high-quality pharmacology data to standardize virtual cell models
New Hevolution–Nanobiosym deal accelerates AI-driven metabolic and ageing diagnostics
AI-driven experiments will map how molecules penetrate tough Gram-negative bacteria
Ageing clocks reveal 27% more drug targets, speeding multi-disease therapy
Insilico’s AI cut drug discovery to 18 months, spurring Lilly’s investment
AI was judged more empathic than doctors using written responses, revealing a system-driven empathy gap
Better global and early-life health data is needed for effective AI aging advances
NHS trial uses AI to analyse MRI scans in minutes, speeding up diagnosis for over 58,000 men yearly
Their goal is to make treatments faster, safer, and more effective
It warns, though, that predictions are not the same as causes
Partnership aims to uncover disease-driving genes and boost precision drug development
From chatbots to diagnostic tools, AI is reshaping patient care across Australia
First BioAgent generated 1,000+ hypotheses, raised $900K, and drove lab testing within weeks
New multi-agent AI analyzes massive datasets to predict biological age in weeks, not years
Machine learning predicted COPD with 86% accuracy, offering hope for earlier, tailored care
The funding will help expand facilities in Boston, San Francisco and London
Review shows machine learning misses over half of high-risk patients, echoing flaws of older tools
PDGrapher outperforms rivals in predicting drug targets and combos for complex diseases
New platform predicts patient drug responses, boosting trial success and cutting development costs